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Background: Antepartum depression is one of the leading causes of maternal morbidity and mortality in the
prenatal period. There is accumulating evidence for the role of brain-derived neurotrophic factor (BDNF) in the
pathophysiology of depression. The present study examines the extent to which maternal early pregnancy serum
BDNF levels are associated with antepartum depression.
Method: A total of 968 women were recruited and interviewed in early pregnancy. Antepartum depression
prevalence and symptom severity were assessed using the Patient Health Questionnaire-9 (PHQ-9) scale. Maternal
serum BDNF levels were measured using a competitive enzyme-linked immunosorbent assay (ELISA). Logistic
regression procedures were performed to estimate odds ratios (OR) and 95% confidence intervals (95% CI)
adjusted for confounders.
Results: Maternal early pregnancy serum BDNF levels were significantly lower in women with antepartum depression
compared to women without depression (mean ± standard deviation [SD]: 20.78 ± 5.97 vs. 21.85 ± 6.42 ng/ml, p = 0.024).
Lower BDNF levels were associated with increased odds of maternal antepartum depression. After adjusting for
confounding, women whose serum BDNF levels were in the lowest three quartiles (<17.32 ng/ml) had
1.61-fold increased odds (OR = 1.61, 95% CI: 1.13, 2.30) of antepartum depression as compared with women
whose BDNF levels were in the highest quartile (>25.31 ng/ml). There was no evidence of an association of BDNF
levels with depression symptom severity.
Conclusions: Lower maternal serum BDNF levels in early pregnancy are associated with antepartum depression. These
findings may point toward new therapeutic opportunities and BDNF should be assessed as a potential biomarker for
risk prediction and monitoring response to treatment for antepartum depression.
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Antepartum depression is a nonpsychotic depressive
episode of mild to moderate severity that presents
during pregnancy [1-3]. Studies have shown that the
prevalence of depression during pregnancy ranges
from 7-15% in high-income countries [2,4] and 19-25% in
low- and middle-income countries [5-7]. Antepartum
depression is of concern because it has been linked to* Correspondence: bgelaye@hsph.harvard.edu
1Department of Epidemiology, Harvard T.H. Chan School of Public Health,
Boston, MA, USA
Full list of author information is available at the end of the article
© 2015 Fung et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.negative health-related behaviors and outcomes, including
poor nutrition, increased substance use, inadequate
prenatal care, preeclampsia, preterm delivery, postnatal
depression, and suicide [8-16]. Infants delivered of women
with untreated antepartum depression are at increased
risk of preterm delivery, growth restriction, low birth
weight, and other neonatal complications [17-23].
Antepartum depression is a complicated phenomenon
which results from the interaction of several psychosocial
and neurobiological factors. A number of studies, primarily
conducted in men and non-pregnant women, have
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brain-derived neurotrophic factor (BDNF). BDNF is a
neurotrophin that is involved in neuronal cell growth,
survival, and synaptic plasticity [24]. Early observations by
Duman et al. indicated that antidepressant drugs increase
the synthesis of BDNF and led to the suggestion that a
deficiency in neurotrophic factor synthesis and signaling
underlie depression and that antidepressants might act by
increasing the levels of BDNF and other neurotrophins
[25,26]. These observations were later followed by findings
supporting a more complex and functional role of BDNF
in depression and antidepressant action [25]. Two recent
meta-analyses of clinical studies indicate that peripheral
blood BDNF levels are decreased in depressed patients
before treatment, and that BDNF levels are increased
following a course of antidepressant treatment [27,28].
There is accumulating evidence, primarily focused on
postpartum period, showing decreased BDNF levels with
the presence of depression [29-31]. One of the major
risk factors for postpartum depression is antepartum
depression [2]. Early detection of antepartum depression
is critical in mitigating risks of postpartum depression as
well as adverse obstetric outcomes. To add to the emerging
literature, we sought to evaluate the extent to which serum
BDNF levels are associated with antepartum depression
among pregnant Peruvian women.
Methods
The PrOMIS Cohort Study
The sample for the present study was drawn from
participants of the ongoing Pregnancy Outcomes,
Maternal and Infant Study (PrOMIS) Cohort, designed to
examine maternal social and behavioral risk factors of
preterm birth and other adverse pregnancy outcomes.
The study population consists of women attending
prenatal care clinics at the Instituto Nacional Materno
Perinatal (INMP) in Lima, Peru. The INMP is the primary
reference establishment for maternal and perinatal care
operated by the Ministry of Health of the Peruvian
government. Recruitment began in February 2012.
Women eligible for inclusion were those who initiated
prenatal care prior to 16 weeks gestation. Women
were ineligible if they were younger than 18 years of age,
did not speak and read Spanish, or had completed more
than 16 weeks gestation.
Enrolled participants were invited to participate in an
interview where trained research personnel used a
structured questionnaire to elicit information regarding
maternal socio-demographic, lifestyle characteristics,
medical and reproductive histories, and early life experi-
ences of abuse and with symptoms of mood and anxiety
disorders. All participants provided written informed
consent. The institutional review boards of the INMP,
Lima, Peru and the Harvard T. H. Chan School of PublicHealth Office of Human Research Administration, Boston,
MA approved all procedures used in this study.
Analytical population
The study population for this report is derived from
information collected from those participants who were
enrolled in the PrOMIS Study between February 2012
and December 2012. During this period, 1,327 eligible
women were approached, and 1,142 (86%) agreed to
participate. Of those participating, 982 provided blood
samples (86%). Fourteen participants were excluded
from the present analysis because of missing information
concerning depressive symptoms. Women excluded from
this analysis did not differ in regards to sociodemographic
and lifestyle characteristics as compared with those
included (Additional file 1: Table S1). A total of 968 women
remained for analysis.
Antepartum depression
Antepartum depression was assessed using the Patient
Health Questionnaire (PHQ-9) which is a nine-item,
self-reported depression measure from the Primary
Care Evaluation of Mental Disorders [32,33] diagnostic
instrument. The instrument was derived from the criteria of
the Diagnostic and Statistical Manual of Mental (DSM-IV)
and assessed nine depressive symptoms, namely, anhedonia,
depressed mood, trouble sleeping, feeling tired, change in
appetite, guilt, or worthlessness, trouble concentrating,
feeling slowed down or restless, and suicidal thoughts,
experienced over the last two weeks (14 days). The
PHQ-9 score was calculated by assigning a score of 0,
1, 2, and 3, to the response categories of “not at all,”
“several days,” “more than half the days” and “nearly every
day” respectively. As a severity measure, the total score of
PHQ-9 ranged from 0 to 27. Depression severity was
determined at cut-off scores of 5, 10, 15 and 20,
representing the thresholds for none, mild, moderate,
moderately severe and severe depression [32]. Possible
major depressive disorder (MDD) was defined as total
score is 10 or greater [32].
PHQ-9 has been widely used for depression screening
in adult primary care setting and hospital settings. It has
been translated in to at least 25 languages [34,35] and
successfully used to measure depression severity among
US African Americans, Asian/Chinese Americans, Latinos,
and non-Hispanic Whites [36,37]. Specifically, the Spanish
language version of the PHQ-9 was tested and found to be
a reliable and efficient screening measure for depression
severity in primary care [38-40] and it has been validated
among both prenatal and postpartum women.
Following structured interviews, maternal non-fasting
blood samples were collected in 7 ml vacutainer tubes
containing K3-EDTA (1 mg/ml). Blood samples were
kept on wet ice and processed within 20 minutes of
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20 minutes at 4°C. Fractions were aliquoted into cryovials
and stored at −80°C until analysis. Serum BDNF levels
were measured using a competitive enzyme-linked
immunosorbent assay (R&D Systems, Minnesota) with
intra- and inter-assay coefficients of variation both <8%.
All assays were performed without knowledge of maternal
antepartum depression status.
Statistical analysis
The distribution of maternal socio-demographic character-
istics, medical and reproductive histories according to
quartiles of maternal serum BDNF levels was examined.
Given our large sample, we used visual inspection of
quantile-quantile (Q-Q) plot and boxplot to check for
normality [41,42]. To estimate the relative association
between varying levels of BDNF and odds of antepartum
depression, we categorized each subject according to
quartiles determined by the distribution of serum
BDNF levels among the entire study population. This pro-
cedure for determining exposure categories for continu-
ous covariates has been previously described by Hsieh et
al. [43]. Using the highest quartile as the referent group,
odds ratios (OR) and 95% confidence intervals (95% CI)
were estimated for each successively lower quartiles.
Logistic regression procedures were used to calculate
maximum likelihood estimates of odds ratios and 95%
confidence intervals, adjusted for potential confound-
ing factors [44]. Confounders were defined as those
factors which altered the unadjusted odds ratios by at least
10%. Maternal illicit drug use, smoking and alcohol con-
sumption during pregnancy were found not to be con-
founders. Maternal age, parity and early pregnancy BMI
were considered to be potential confounders. In mul-
tivariable logistic regression models, significance for
monotonic trends in risk between odds of antepartum de-
pression and serum BDNF levels were assessed by
treating the four quartiles as a continuous variable
after assigning a score as its value. All reported p values
are two sided. All analyses were completed using SAS 9.3
(SAS Institute, Cary, NC, USA).
Results
Characteristics of study participants distributed according
to quartiles of maternal early pregnancy serum BDNF levels
are summarized in Table 1. Briefly, women with higher
BDNF levels tended to be older, multiparous, heavier and
were more likely to report having planned the current
pregnancy. Approximately 28.9% of this cohort of pregnant
women met the diagnostic criteria for antepartum
depression on the basis of their PHQ-9 score: ≥10. As
shown in Table 2, depressed women had lower mean
serum BDNF levels as compared with non-depressed
women (mean ± standard deviation [SD]: 20.78 ± 5.97 vs21.85 ± 6.42 ng/ml, p = 0.024). As shown in the bottom
panel of Table 2, there was no evidence of a linear trend
of increasing BDNF levels with increasing severity of
depressive symptoms (p = 0.144).
Multivariate adjusted ORs for maternal antepartum
depression in relation to maternal early pregnant BDNF
levels are reported in Table 3. The adjusted ORs (95% CI)
for antepartum depression are 1.51 (0.99-2.30), 1.66
(1.09-2.52), 1.67 (1.10-2.53), and 1.00 for successive
quartiles (lowest to highest quartile), with the highest
quartile as the referent group. There was no evidence
of a statistically significant linear trend in odds of
antepartum depression across decreasing quartile of
BDNF (p-value = 0.082). Given the similar magnitude
of risks, we collapsed the upper three quartiles and
repeated analyses. As shown in the bottom panel of
Table 3, compared with BDNF levels in the highest
quartile (>25.31 ng/ml), women with lower levels
(≤25.31 ng/ml) had a 1.61-fold higher odds of antepartum
depression (OR = 1.61; 95% CI: 1.13-2.30) after adjustments
for confounding factors including maternal age, parity and
early pregnancy body mass index.
Discussion
Overall, we found that pregnant women with lower early
pregnancy serum BDNF levels, a well-studied neurotropic
peptide, had higher odds of antepartum depression as com-
pared with their counterparts who had higher levels. After
adjusting for confounders, women whose serum BDNF
levels were in the lowest three quartiles (≤25.31 ng/ml) had
1.61-fold increased odds (OR = 1.61; 95% CI: 1.13, 2.30) of
antepartum depression as compared with women whose
BDNF levels were in the highest quartile (>25.31 ng/ml).
To the best our knowledge, this is the first large study
to examine maternal early pregnancy serum BDNF levels
and antepartum depression. Our findings are consistent
with most [45-48] though not all [31,49,50] prior studies of
BDNF levels and depression among men and non-pregnant
women. In their study of adolescents, Pallavi et al. noted
that treatment naïve adolescents with depression (n = 64)
had significantly lower mean serum BDNF levels as
compared with healthy controls (n = 64) (8.27 ± 0.39
vs. 10.30 ± 0.39 ng/ml; p < 0.001). The authors also reported
that BDNF levels were inversely correlated with Beck’s
inventory score (BDI-II) (ρ = −0.32, p < 0.01) [46].
Satomura et al., in their study of men and non-pregnant
women with major depressive disorder, reported statisti-
cally significant inverse associations of serum BDNF level
with Hamilton rating scale for depression (HAM-D) score
(n = 109, ρ = −0.19, p = 0.044) [47]. Participants classified
as depressed on the HAM-D had statistically significantly
lower mean BDNF levels as compared with non-depressed
participants (20.32 ± 8.18 vs. 27.10 ± 8.31 ng/ml; p < 0.001).
Similarly, Karege et al. reported decreased mean serum
Table 1 Characteristics of study participants according to quartiles of maternal serum brain-derived neurotrophic
factor (BDNF, ng/mL) levels, PrOMIS Cohort Study, Lima, Peru, 2012
Characteristics Serum brain-derived neurotrophic factor (BDNF, ng/ml) **P-value
Quartile 1 Quartile 2 Quartile 3 Quartile 4
(<17.32) (17.32-20.92) (20.92-25.31) (>25.31)
N = 242 N = 242 N = 242 N = 242
n % n % n % n %
Maternal age (years)* 26.4 ± 5.9 27.3 ± 6.3 28.7 ± 6.0 29.7 ± 6.4 0.001
Maternal age (years)
18-20 26 10.7 20 8.3 8 3.3 6 2.5 0.091
20-29 151 62.4 142 58.7 132 54.5 121 50.0
30-34 34 14.0 41 16.9 58 24.0 59 24.4
≥35 31 12.8 39 16.1 44 18.2 56 23.1
Gestational age at Interview* (weeks) 10.96 ± 3.5 10.51 ± 3.31 9.6 ± 3.40 8.56 ± 3.11 0.48
Education (years)
≤6 10 4.1 7 2.9 10 4.2 11 4.5 0.42
7-12 141 58.3 142 59.2 144 60.0 124 51.2
>12 91 37.6 91 37.9 86 35.8 107 44.2
Hispanic Ethnicity 179 74.3 186 76.9 180 74.4 186 76.9 0.67
Married/living with partner 190 79.2 194 80.5 192 80.0 201 83.4 0.28
Employed 104 24.2 95 22.1 117 27.3 113 26.3 0.15
Access to basic foods
Hard 127 52.5 136 56.2 119 49.2 130 53.7 0.82
Not very hard 115 47.5 106 43.8 123 50.8 112 46.3
Nulliparous 134 55.4 124 51.2 125 51.7 100 41.3 0.004
Planned pregnancy 82 19.7 111 26.6 110 26.4 114 27.3 0.005
Early pregnancy body mass index (kg/m2)
<25 143 59.8 136 56.7 107 44.6 93 38.6 0.026
25-29.9 81 33.9 88 36.7 89 37.1 101 41.9
≥30 15 6.3 16 6.7 44 18.3 47 19.5
Illicit drug use during pregnancy 4 1.7 3 1.2 1 0.4 1 0.4 0.10
Smoked during pregnancy 13 5.4 16 6.8 7 2.9 8 3.3 0.09
Consumed alcohol during pregnancy 56 23.3 42 17.4 69 28.5 50 20.7 0.79
Due to missing data, percentages may not add up to 100%.
*Mean ± SD (standard deviation).
**P-value of test of linear trend.
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pared with healthy controls (n = 30) who were
matched to cases on sex and age (22.60 ± 3.00 vs.
26.50 ± 7.00 ng/ml; p < 0.001) [45]. Varambally et al.
found that 43 antidepressant-naive out-patients with
depression (assessed using the Mini International
Neuropsychiatric Interview) had statistically significantly
lower mean serum BDNF level (18.6 ± 4.9 ng/ml) as
compared with 24 age-matched healthy controls
(23.6 ± 5.6 ng/ml; p < 0.001) [48]. Recently Azevedeo
Cardoso and colleagues, in their study of 120 depressed
participants and 120 healthy controls (matched for sex,
age and tobacco use), noted that mean serum BDNF levelswere statistically significantly lower in depressed subjects
as compared with controls (4.65 ± 4.18 vs. 7.37 ± 2.31 ng/ml
p < 0.001) [51]. On balance, our observation of increased
odds of antepartum depression with lower BDNF levels in
early pregnancy are consistent with these earlier studies
that have principally focused on adolescents, men and
non-pregnant women.
Our results, however, are not consistent with findings
reported by some other investigators. For instance,
Pinheiro et al., in their study of 29 depressed and 161
non-depressed Brazilian postpartum women, found no
statistically significant differences in mean serum BDNF
levels for postpartum depressed and non-depressed women
Table 2 Distribution of maternal serum brain-derived neurotrophic factor (BDNF, ng/mL) levels in early pregnancy
according to antepartum depressive symptoms, Lima, Peru, 2012
Depression N Mean ± SD Median [IQR]* P-value
Depression
No (0–9) 688 21.85 ± 6.42 21.22 [17.37-25.85] 0.024**
Yes (≥10) 280 20.78 ± 5.97 20.31 [17.08-24.20]
Depression severity
None (0–4) 334 21.99 ± 6.76 21.63 [17.30-26.55] 0.144***
Mild (5–9) 354 21.73 ± 6.09 21.15 [17.63-25.62]
Moderate (10–14) 158 20.42 ± 6.31 20.17 [16.68-24.03]
Moderately severe (15–19) 88 21.11 ± 5.82 20.08 [17.20-24.45]
Severe (20–27) 34 21.67 ± 4.54 21.36 [18.06-24.30]
*IQR = Interquartile range.
**P-value was calculated using Wilcoxon Rank Sum Test.
***P-value was calculated using Kruskal-Wallis Test.
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However, the authors noted that women with postpartum
depression and suicidality had statistically significantly
lower mean BDNF levels as compared to women
without postpartum depression and suicidality (1.50 ± 1.38
vs. 2.32 ± 1.28 ng/ml, p = 0.026) [31]. In their study of 139
participants with major depressive disorder Jevtovic et al.,
found that serum BDNF levels were not significantly asso-
ciated with severity of depression as assessed by HAM-D
(p = 0.169) [49]. Mean serum BDNF levels in patients
with mild, moderately severe and severe forms of
depression were 41.7 ± 14.5 ng/ml, 36.4 ± 14.8 ng/ml,
and 42.1 ± 11.1 ng/ml respectively [49].
The inconsistency of results across studies may be
attributable to a number of factors including differences in
study populations (e.g., differing underlying distributions
treated and un-treated patients), study settings, operational
definitions of depression and depressive symptom severity.
In addition, the relatively small size of some studies,
particularly those failing to document associations of BDNF
levels with depression, may have had limited the statistical
power for testing their study hypotheses. It is possible thatTable 3 Odds ratio (OR) and 95% confidence interval (CI) for
(BDNF, ng/mL) levels in early pregnancy in relation to antepa
BDNF levels (ng/ml) Antepartum depression
Yes (N = 280) No
n % N
Quartile 1 (<17.32) 75 26.8 167
Quartile 2 (17.32-20.92) 78 27.9 164
Quartile 3 (20.92-25.31) 76 27.1 166
Quartile 4 (>25.31) 51 18.2 191
P-value for linear trend
Quartile 1–3 (≤25.31) 229 81.8 497
Quartile 4 (>25.31) 51 18.2 191
*Adjusted for maternal age, parity, and early pregnancy body mass index.variation in sensitivities of assays used in prior studies may
have contributed to variations in reported absolute values
of BDNF levels observed across studies; and that varia-
tions in assays may have contributed to inconsistent find-
ings. The overall mean BDNF levels, irrespective of
depressive symptoms, reported in our study are compar-
able with most prior studies [45,47,48]. However, the mean
BDNF levels in our study are higher than those reported by
Azevedeo Cardoso et al. [51] and Pinheiro et al. [31] but
lower than Jevtovic et al. [49]. Although a large number of
studies have determined serum BDNF levels using ELISA
kits, the variability noted in overall mean BDNF levels irre-
spective of depression status might be reflective of pre-
analytical conditions of BDNF assessment [52]. BDNF levels
are also known to vary depending on participants’ age, eth-
nicity, and diet habits [51,53,54].
Observed associations of increased odds of antepartum
depression with decreased BDNF is biologically plausible.
BDNF, an important and well-studied, neurotrophic factor,
has been shown to play a critical role in neurogenesis
and neural plasticity [55]. A study using RNA interference
and lentiviral vectors to knockdown BDNF expression inmaternal serum brain-derived neurotrophic factor




(95% CI)*(N = 688)
%
24.3 1.68 (1.11, 2.54) 1.51 (0.99, 2.30)
23.8 1.78 (1.18, 2.68) 1.66 (1.09, 2.52)
24.1 1.71 (1.14, 2.59) 1.67 (1.10, 2.53)
27.8 Reference Reference
0.019 0.082
72.2 1.73 (1.22, 2.44) 1.61 (1.13, 2.30)
27.8 Reference Reference
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depressive behaviors and impaired neuronal differentiation
[56]. Other animal models have examined factors that
influence BDNF expression and levels in peripheral circula-
tion. Franklin and Sinal [57] demonstrated that stress
down-regulates BDNF mRNA and protein expression in
the hippocampus and other brain regions in rodents.
Moreover, administration of synthetic glucocorticoid,
dexamethasone, in pigs has been shown to result in
decreased BDNF mRNA expression in all hippocampal
regions [58]. Collectively, these studies in diverse animal
models are consistent with the notion that reduction
in BDNF levels may be causally related to depression
and depressive symptoms. Of note, in autopsy studies, in-
creased BDNF expression was found in hippocampal re-
gions in subjects with a history of being treated with
antidepressant medications as compared with un-
treated subjects [59,60].
Findings from clinical studies suggest that normalization
of BDNF levels in peripheral blood samples may be pre-
dictive of antidepressant treatment response [61]. A num-
ber of clinical studies have documented increases in
serum or plasma BDNF levels after 6 to 8 weeks of treat-
ment among patients who responded to antidepressants,
while no similar increases were evident among patients
who failed to respond to antidepressants [62-64]. For ex-
ample, in a small study involving 41 patients with major
depression, low serum BDNF levels predicted treat-
ment failure and higher depressive symptomology
[63]. On balance, available evidence suggest that low BDNF
is predictive of incident [65] and prevalent [46,47] depres-
sion and that normalization of BDNF levels may be indica-
tive of treatment of depression [62-64]. Additional studies
focused on the relationship of BDNF with the incidence
and course of depression during the antepartum and post-
partum periods are warranted.
The strengths of our study include a large sample size, the
inclusion of antidepressant-naïve study population, use of
well-trained interviewers, and rigorous analytic approaches
that included accounting for confounding control. However,
limitations to our study must also be acknowledged. The
cross-sectional design of the present study does not allow
for an empirical assessment of the temporal relationship of
alterations in BDNF levels and occurrence or onset of ante-
partum depression. Longitudinal studies with serial blood
sampling, determination of BDNF levels, and assessment of
depressive symptoms will enhance causal inference in this
line of research. Although the PHQ-9 has been validated
and has documented to be an efficient screening tool for de-
pression in adult primary care and hospital settings
[51,66,67], the possibility of misclassification of depression
remains. The impact of potential non-differential misclassifi-
cation of participants’ depression status in this study is not
likely to be related to measured BDNF levels (testing wascompleted in a blinded manner). Hence, we speculate that
any misclassification in maternal antepartum depression sta-
tus is generally likely to have resulted in an underestimation
of the true magnitude of association between lower BDNF
levels and antepartum depression risk. The concordance of
our study findings with other studies [45-48] that used
screening and diagnostic instruments serve to attenuate
concerns about misclassification of depression status. Al-
though we used multivariable logistic regression procedures
to adjust for putative confounders, we cannot exclude the
possibility of residual confounding. Another important limi-
tation that merits consideration is measurement of BDNF
levels. Studies have shown that BDNF is first synthesized as
a precursor proBDNF, which is proteolytically cleaved to
generate mature BDNF [68-70]. Recent studies have dem-
onstrated that proBDNF and mature BDNF facilitate long-
term depression and long-term potentiation, respectively,
implying opposing cellular functions [69,70]. The ELISA
assay used in our study measured the total of BDNF levels
(proBDNF and mature BDNF combined), and thus we were
not able to assess possible differences of antepartum depres-
sion in the relation with proBDNF and mature BDNF. As-
sessment of proBDNF and mature BDNF levels in future
studies is warranted [68].Conclusion
Early detection of antepartum depression and effective
interventions intended to manage symptoms are critical
to prevent adverse perinatal outcomes particularly for
socioeconomically disadvantaged women in developing
countries and in the United States [4,71]. However, antepar-
tum depression is often under recognized and untreated
[72,73]. Currently, depression diagnosis and treatment
response relies on interview-based assessments of subject-
ive self-reported symptoms. The results of our study and
those of others [45-47] raise the possibility that serum
BDNF levels may point toward new therapeutic opportun-
ities, and suggest that BDNF should be evaluated as a pos-
sible biomarker for risk prediction and monitoring
response to treatment for antepartum depression. Longi-
tudinal data with serial measures of BDNF levels and as-
sessments of depressive disorders during pregnancy and
the postpartum periods of pregnancy are warranted.Additional file
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